CN103764659A - 抑制胶质母细胞瘤的化合物及其用途 - Google Patents

抑制胶质母细胞瘤的化合物及其用途 Download PDF

Info

Publication number
CN103764659A
CN103764659A CN201280028960.8A CN201280028960A CN103764659A CN 103764659 A CN103764659 A CN 103764659A CN 201280028960 A CN201280028960 A CN 201280028960A CN 103764659 A CN103764659 A CN 103764659A
Authority
CN
China
Prior art keywords
glioblastoma
compound
cells
gene encoding
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280028960.8A
Other languages
English (en)
Chinese (zh)
Inventor
比约恩·舍夫勒
马丁·格拉斯
马蒂亚斯·西蒙
扎比内·戈戈洛克
丹尼尔·特拉格泽
罗曼·赖纳茨
安雅·维兰德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rheinische Friedrich Wilhelms Universitaet Bonn
Life and Brain GmbH
Original Assignee
Rheinische Friedrich Wilhelms Universitaet Bonn
Life and Brain GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rheinische Friedrich Wilhelms Universitaet Bonn, Life and Brain GmbH filed Critical Rheinische Friedrich Wilhelms Universitaet Bonn
Publication of CN103764659A publication Critical patent/CN103764659A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/06—Peri-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280028960.8A 2011-06-15 2012-06-15 抑制胶质母细胞瘤的化合物及其用途 Pending CN103764659A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161497215P 2011-06-15 2011-06-15
US61/497,215 2011-06-15
PCT/EP2012/061485 WO2012172069A1 (en) 2011-06-15 2012-06-15 Glioblastoma inhibiting compounds and their use

Publications (1)

Publication Number Publication Date
CN103764659A true CN103764659A (zh) 2014-04-30

Family

ID=46319762

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280028960.8A Pending CN103764659A (zh) 2011-06-15 2012-06-15 抑制胶质母细胞瘤的化合物及其用途

Country Status (14)

Country Link
US (1) US9573960B2 (enExample)
EP (1) EP2721035B1 (enExample)
JP (1) JP6228113B2 (enExample)
CN (1) CN103764659A (enExample)
AU (1) AU2012268984B2 (enExample)
BR (1) BR112013032360A2 (enExample)
CA (1) CA2838945A1 (enExample)
CL (1) CL2013003563A1 (enExample)
IL (1) IL229767A0 (enExample)
MX (1) MX340816B (enExample)
PH (1) PH12013502530A1 (enExample)
RU (1) RU2014101070A (enExample)
WO (1) WO2012172069A1 (enExample)
ZA (1) ZA201309365B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105796549A (zh) * 2016-04-22 2016-07-27 中国医学科学院基础医学研究所 藤黄酰胺用于制备治疗人神经胶质瘤的药物的用途
CN105802928A (zh) * 2016-03-30 2016-07-27 苏州偲聚生物材料有限公司 用于检测血清中mgmt抗体的多肽，检测器件和检测试剂盒
CN117538458A (zh) * 2024-01-09 2024-02-09 中国医学科学院北京协和医院 同时定量分析14种单糖/二糖的液相色谱串联质谱分析方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014023329A1 (en) * 2012-08-06 2014-02-13 Life And Brain Gmbh Niclosamide and its derivatives for use in the treatment of solid tumors
US10905665B2 (en) 2015-06-24 2021-02-02 Duke University Chemical modulators of signaling pathways and therapeutic use
US20180209959A1 (en) * 2015-07-31 2018-07-26 Swedish Health Services Methods and compositions for characterization of glioblastoma multiforme tumors and cancer stem cells
CA2998472A1 (en) 2015-09-15 2017-03-23 Swedish Health Services Methods and panels of compounds for characterization of glioblastoma multiforme tumors and cancer stem cells thereof
CN107475213A (zh) * 2016-06-08 2017-12-15 中国科学院苏州纳米技术与纳米仿生研究所 用于检测血清中mgmt抗体的多肽，检测器件和检测试剂盒
WO2019178059A1 (en) * 2018-03-13 2019-09-19 Georgetown University ENHANCING CHEMOTHERAPY IN MEDULLOBLASTOMA AND GLIOBLASTOMA WITH HIGH BASAL p53 LEVELS
CN110433154A (zh) * 2019-08-12 2019-11-12 昆明理工大学 藤黄酸的新用途
US20250205225A1 (en) * 2022-03-23 2025-06-26 University Of Cincinnati Methods of potentiating temozolomide activity against glioblastoma cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1300403A1 (en) * 2001-10-02 2003-04-09 Aventis Pharma S.A. Process for the manufacture of hypoxyxylerone derivatives
US20030078292A1 (en) * 1999-05-21 2003-04-24 Cytovia, Inc. Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis
CN101289482A (zh) * 2007-09-29 2008-10-22 辽宁利锋科技开发有限公司 藤黄酸苷衍生物和类似物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2396005A1 (en) * 1999-02-01 2000-08-03 Cytovia, Inc. Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis
AU2864100A (en) * 1999-02-01 2000-08-18 Cytovia, Inc. Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products
JP3904364B2 (ja) 2000-03-03 2007-04-11 独立行政法人科学技術振興機構 抗マラリア活性を有する新規化合物
WO2008148008A1 (en) * 2007-05-23 2008-12-04 Emory University High throughput bioassay for identifying selective trka receptor agonists, and gambogic amide, a selective trka agonist with neuroprotective activity
PA8851101A1 (es) * 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078292A1 (en) * 1999-05-21 2003-04-24 Cytovia, Inc. Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis
EP1300403A1 (en) * 2001-10-02 2003-04-09 Aventis Pharma S.A. Process for the manufacture of hypoxyxylerone derivatives
CN101289482A (zh) * 2007-09-29 2008-10-22 辽宁利锋科技开发有限公司 藤黄酸苷衍生物和类似物及其制备方法和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PENG JIN-YONG等: "Separation of Two New Prenylated Dihydroflavonoids from Dolichos tenuicaulis (Baker) Craib by High-speed Counter-current Chromatography", 《CHINESE JOURNAL OF ANALYTICAL CHEMISTRY》, vol. 35, no. 10, 31 October 2007 (2007-10-31), pages 1444 - 1448, XP022857804, DOI: 10.1016/S1872-2040(07)60087-5 *
冯锋等: "藤黄酸衍生物的研究", 《中国药科大学学报》, vol. 36, no. 4, 31 December 2005 (2005-12-31), pages 302 - 305 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105802928A (zh) * 2016-03-30 2016-07-27 苏州偲聚生物材料有限公司 用于检测血清中mgmt抗体的多肽，检测器件和检测试剂盒
CN105796549A (zh) * 2016-04-22 2016-07-27 中国医学科学院基础医学研究所 藤黄酰胺用于制备治疗人神经胶质瘤的药物的用途
WO2017181799A1 (zh) * 2016-04-22 2017-10-26 中国医学科学院基础医学研究所 藤黄酰胺用于制备治疗人神经胶质瘤的药物的用途
CN117538458A (zh) * 2024-01-09 2024-02-09 中国医学科学院北京协和医院 同时定量分析14种单糖/二糖的液相色谱串联质谱分析方法
CN117538458B (zh) * 2024-01-09 2024-03-29 中国医学科学院北京协和医院 同时定量分析14种单糖/二糖的液相色谱串联质谱分析方法

Also Published As

Publication number Publication date
JP6228113B2 (ja) 2017-11-08
CL2013003563A1 (es) 2014-06-06
JP2014517025A (ja) 2014-07-17
MX2013014708A (es) 2014-08-18
IL229767A0 (en) 2014-01-30
MX340816B (es) 2016-07-26
WO2012172069A1 (en) 2012-12-20
ZA201309365B (en) 2015-11-25
US20150148390A1 (en) 2015-05-28
US9573960B2 (en) 2017-02-21
NZ618170A (en) 2015-04-24
CA2838945A1 (en) 2012-12-20
EP2721035B1 (en) 2018-06-13
AU2012268984B2 (en) 2016-07-14
BR112013032360A2 (pt) 2017-06-13
PH12013502530A1 (en) 2014-01-27
RU2014101070A (ru) 2015-07-20
EP2721035A1 (en) 2014-04-23

Similar Documents

Publication Publication Date Title
EP2721035B1 (en) Glioblastoma inhibiting compounds and their use
AU2012268984A1 (en) Glioblastoma inhibiting compounds and their use
US9844522B2 (en) Niclosamide and its derivatives for use in the treatment of solid tumors
US8507546B2 (en) Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
US10207998B2 (en) Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
US20070293491A1 (en) Indazole compounds and methods for inhibition of cdc7
US20170044127A1 (en) Icariin derivatives
EP3108883A1 (en) Therapeutic uses of non-peptide inhibitors of the calcineurin - nfat signalling pathway
US9724331B2 (en) Use of maleimide derivatives for preventing and treating leukemia
US20220073519A1 (en) Compounds For Repressing Cancer Cell Growth
CN106831799B (zh) 羟基苯乙烯吡啶曼尼希碱类化合物、其制备方法和用途
US20240376080A1 (en) Compound as tyk2/jak1 pseudokinase domain inhibitor, and synthesis and use methods
NZ618170B2 (en) Glioblastoma inhibiting compounds and their use
CN114478318B (zh) 二腈异佛尔酮衍生物、其制备方法及应用
EP3381910B1 (en) 4-oxo-4,5-dihydrothiazole derivative, preparation method and use thereof
TW202530200A (zh) 嗒𠯤酮類化合物作為泛素－特異性蛋白酶１抑制劑的製備方法、應用及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140430